文献速递鼻科

变应原特异性免疫治疗用于局部变应性鼻炎:系统评价与荟萃分析

Allergen-specific immunotherapy for local allergic rhinitis: a systematic review and meta-analysis.
PubMed 文献 · Rhinology · 2022-01-01

该系统评价与荟萃分析检索六个电子数据库及注册库,纳入变应原特异性免疫治疗(AIT)用于局部变应性鼻炎(LAR)患者的实验性与观察性研究,主要结局为症状评分、用药评分、联合症状用药评分及疾病特异性生活质量。四项双盲随机对照试验(156例患者)评估皮下免疫治疗(SCIT),与安慰剂相比SCIT显著降低症状评分、用药评分、联合症状用药评分、疾病特异性生活质量并升高血清sIgG4,血清sIgE无显著变化;两项观察性研究显示治疗后症状评分改善;AIT安全无严重不良事件,但效果仅限于短期随访研究。

要点

  • SCIT可显著改善LAR患者症状评分、用药评分、联合评分及生活质量。
  • SCIT升高血清sIgG4,但血清sIgE无显著变化。
  • AIT安全无严重不良事件,但证据仅限短期随访。

核心结论

  • AIT对局部变应性鼻炎具有有益效果且安全,可考虑用于LAR患者。
  • AIT的效果仅限于短期随访的研究,停药后效果尚无研究评估。

研究设计与样本

  • 系统检索六个电子数据库和注册库,纳入AIT用于LAR患者的实验性和观察性研究。
  • 四项双盲随机对照试验共156例患者来自两个研究单位,评估皮下免疫治疗(SCIT)的效果。
  • 两项观察性研究分别使用SCIT和舌下免疫治疗,评估治疗后症状评分。

主要发现

  • 与安慰剂相比,SCIT显著降低症状评分、用药评分、联合症状用药评分和疾病特异性生活质量。
  • 与安慰剂相比,SCIT显著升高血清sIgG4,血清sIgE无显著变化。
  • 两项观察性研究显示AIT治疗后症状评分改善。
  • AIT安全,无严重不良事件报告。

关键数值与推荐

  • 主要结局为症状评分、用药评分、联合症状用药评分和疾病特异性生活质量。
  • 次要结局为血清特异性IgG4、特异性IgE和不良事件。

临床怎么用

  • AIT可考虑用于局部变应性鼻炎患者。
  • 临床决策需注意现有证据仅来自短期随访研究,停药后效果未知。

局限性

  • 无研究评估停止治疗后的效果。
  • AIT的效果仅限于短期随访的研究。
  • 随机对照试验仅来自两个研究单位,共156例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Local allergic rhinitis (LAR) is a phenotype of chronic rhinitis exhibiting a local Th2-driven inflammation without positive clinical markers of atopy. Immunomodulatory effects of allergen-specific immunotherapy (AIT) induce allergen-specific tolerance. However, AIT is not well-recognized as a treatment for LAR. METHODOLOGY: Systematic search on six electronic databases and registries was performed. Experimental and observational studies of AIT for LAR patients were retrieved. The primary outcomes were symptom score, medication score, combined symptom medication score, and disease-specific quality of life. Secondary outcomes were serum specific(s) IgG4, sIgE, and adverse events. RESULTS: Four double-blind randomized controlled trials (156 patients) from two research units assessed the effects of subcutaneous immunotherapy (SCIT). Compared with placebo, SCIT showed significant reductions in symptom score, medication score, combined symptom medication score, disease-specific quality of life, and an increase in serum sIgG4. There was no significant change in serum sIgE. Likewise, two observational studies (one using SCIT and one using sublingual immunotherapy) improved post-therapeutic symptom score. No studies assessed the effects after discontinuation of treatment. AIT was safe without serious adverse events. CONCLUSION: AIT has beneficial effects and safe for LAR. Its effects are restricted to studies with short-term follow-up. AIT may be considered in LAR patients.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Hoang MP, Samuthpongtorn J, Chitsuthipakorn W, et al. Allergen-specific immunotherapy for local allergic rhinitis: a systematic review and meta-analysis. Rhinology. 2022. PMID: 34609382. doi:10.4193/Rhin21.193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。